EF
SRPT icon

Empowered Funds’s Sarepta Therapeutics SRPT Stock Holding History

Empowered Funds’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-23,235
Closed -$3.01M – 694
2022
Q4 		$3.01M Buy
+23,235
New +$2.69M 0.2% 150

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Empowered Funds's SRPT Position: Q1 2026 in Review

Empowered Funds opened a new position in Sarepta Therapeutics (SRPT) in Q1 2026: 113,935 shares worth $2.48M. The stake represents 0.02% of the portfolio and ranks #987 among its holdings. This is a return to the name: Empowered Funds previously reported a position in SRPT as recently as Q4 2023.

Empowered Funds first reported a position in SRPT in Q1 2018 and has held it in 5 quarters since. The position peaked at $3.07M in Q1 2023. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Empowered Funds held 113,935 shares of Sarepta Therapeutics worth $2.48M as of Q1 2026.
  • Sarepta Therapeutics was a new Empowered Funds position in Q1 2026.
  • Sarepta Therapeutics made up 0.02% of Empowered Funds's portfolio in Q1 2026, its #987 holding.
  • Empowered Funds first reported a position in Sarepta Therapeutics in Q1 2018 and has held it in 5 quarters since.
  • Empowered Funds's Sarepta Therapeutics position peaked at $3.07M in Q1 2023.
  • 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Empowered Funds's 13F filing for Q1 2026, filed 15 May 2026.